Meizon Innovation

🗓 Founded 2018👥 7 employees💰 Last funded Dec 2024
Biotechnology Research🌐 meizon.health
Website LinkedIn
DL33 and M08 are pioneering treatments aimed at and addressing neurological conditions like dementia and autism. They offer new hope for improving quality of life and advancing neurological care. “To make a difference, you must be different.” By leading with cutting-edge science and a global vision, Meizon strives to maximize health outcomes for society. Together we are bringing hope and aim to provide relief to millions around the world. Dementia and autism are global health crises impacting millions, necessitating innovative solutions for improved outcomes. Dementia affects 55 million people globally, leading to significant disability and economic costs of over US$1.3 trillion annually. Autism Spectrum Disorder impacts one in every 36 children in the US as of 2020, and expected to affect one in 25 children in Australia in 2024. Childhood Dementia accounts for 700,000 cases and 48,300 premature deaths worldwide each year.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Australia
1
Frequently asked questions
Who invested in Meizon Innovation?
Meizon Innovation has 1 investors on record on gritt.io and 1 late-stage investors.
When did Meizon Innovation last raise funding?
The most recent investment in Meizon Innovation recorded on gritt.io was in December 2024.
When was Meizon Innovation founded?
Meizon Innovation was founded in 2018.
What industry is Meizon Innovation in?
Meizon Innovation operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.